《新股消息》深藍科技(01950.HK)今日起招股 每手入場費2,424.2元
中國人工革化學品製造商深藍科技(01950.HK)公布,計劃總發行2.5億股新股,10%在港公開發售,90%為國際配售。每股招股價介乎0.5元至0.6元,每手4,000股,入場費2,424.18元,由今日(27日)起至下周二(3月3日)公開招股。該股預計3月12日上市,智富為獨家保薦人。
若以招股中間價0.55元計算,公司預計所得款項淨額為9,140萬元,60%用於在現有建德生產廠房附近興建新生產廠房及購買新機器及設備;16.4%用於強化自動化系統;21.8%用於透過將現有研究院遷至現有建德生產廠房,以及委聘更多有經驗的專家及工程師,和購入更多先進的研發設備及測試設備以增強研發能力等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.